Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 27, 2019 - Issue 1
Submit an article Journal homepage
3,873
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials

Hiroshi GotoDepartment of Ophthalmology, Tokyo Medical University, Tokyo, JapanView further author information
,
Masahiro ZakoDepartment of Ophthalmology, Asai Hospital, Aichi, JapanView further author information
,
Kenichi NambaDepartment of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JapanView further author information
,
Noriyasu HashidaDepartment of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, JapanView further author information
,
Toshikatsu KaburakiDepartment of Ophthalmology, The University of Tokyo Graduate School of Medicine, Tokyo, JapanView further author information
,
Masanori MiyazakiDepartment of Ophthalmology, Kyushu University Graduate School of Medicine, Fukuoka, JapanView further author information
,
Koh-Hei SonodaDepartment of Ophthalmology, Kyushu University Graduate School of Medicine, Fukuoka, JapanView further author information
,
Toshiaki AbeDivision of Clinical Cell Therapy, Tohoku University Graduate School of Medicine, Miyagi, JapanView further author information
,
Nobuhisa MizukiDepartment of Ophthalmology, Yokohama City University School of Medicine, Yokohama, JapanView further author information
,
Koju KamoiDepartment of Ophthalmology & Visual Science, Tokyo Medical and Dental University, Tokyo, JapanView further author information
,
Antoine P. BrézinCentre d’ophtalmologie de l’Assistance Publique, Hôpitaux de Paris, Hôpital Cochin, Université Paris Descartes, Paris, FranceView further author information
,
Andrew D. DickUniversity of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, and National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London, Institute of Ophthalmology, London, UK.View further author information
,
Glenn J. JaffeDuke Eye Center, Duke University Hospital, Durham, North Carolina, USAView further author information
,
Quan Dong NguyenDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USAView further author information
,
Noritaka InomataAbbVie GK Japan, Tokyo, JapanView further author information
,
Nisha V. KwatraAbbVie Inc., North Chicago, Illinois, USAView further author information
,
Anne CamezAbbVie Deutschland GmbH & Co KG, Ludwigshafen, GermanyView further author information
,
Alexandra P. SongAbbVie Inc., North Chicago, Illinois, USACorrespondence[email protected]
View further author information
,
Martina KronAbbVie Deutschland GmbH & Co KG, Ludwigshafen, GermanyView further author information
,
Samir TariAbbVie Inc., North Chicago, Illinois, USAView further author information
&
Shigeaki OhnoDepartment of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JapanView further author information
 show all
Pages 40-50 | Received 07 Dec 2017, Accepted 18 Jun 2018, Published online: 17 Jul 2018

References

  • Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1–13.
  • Jabs DA. Epidemiology of uveitis. Ophthalmic Epidemiol. 2008;15:283–284. doi:10.1080/09286580802478724.
  • Kempen JH, Gewaily DY, Newcomb CW, et al. Remission of intermediate uveitis: incidence and predictive factors. Am J Ophthalmol. 2016;164:110–117 e112. doi:10.1016/j.ajo.2015.12.034.
  • Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81. doi:10.2147/btt.s41477.
  • Becker MD, Smith JR, Max R, Fiehn C. Management of sight-threatening uveitis: new therapeutic options. Drugs. 2005;65:497–519.
  • Cervantes-Castaneda RA, Jawed N, Foster CS. Immunosuppressive therapy for noninfectious uveitis. Retinal Physician. 2007;4:30–38.
  • Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
  • Beckham JC, Caldwell DS, Peterson BL, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol. 1992;12:353–361.
  • Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol. 1992;4:754–759.
  • Rabinovich CE. Use of tumor necrosis factor inhibitors in uveitis. Curr Opin Rheumatol. 2007;19:482–486. doi:10.1097/BOR.0b013e32825f5481.
  • Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet’s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128–132.
  • Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524. doi:10.1136/annrheumdis-2011-201244.
  • Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–943. doi:10.1056/NEJMoa1509852.
  • Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–1192. doi:10.1016/S0140-6736(16)31339-3.
  • Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
  • Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–471.
  • Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41–44. doi:10.1007/s10384-006-0383-4.
  • Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432–435. doi:10.1007/s10384-012-0158-z.
  • Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47:339–344. doi:10.1093/rheumatology/kem356.
  • Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351–361. doi:10.1089/jop.2007.0104.
  • Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.
  • Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481–486.doi:10.1136/bjophthalmol-2012-302292.
  • Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: A multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016;68:1522–1530. doi:10.1002/art.39667.
  • HUMIRA (adalimumab). Full Prescribing Information. North Chicago, IL: AbbVie Inc.; 2014.
  • Diaz-Llopis M, Gallego-Pinazo R, Garcia-Delpech S, Salom-Alonso D. General principles for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets. 2009;8:260–265.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.